Last €52.95 EUR
Change Today -0.24 / -0.45%
Volume 0.0
BL9B On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 3:52 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

balchem corp (BL9B) Snapshot

Open
€52.93
Previous Close
€53.19
Day High
€53.31
Day Low
€52.93
52 Week High
11/11/14 - €54.70
52 Week Low
03/4/14 - €35.50
Market Cap
1.6B
Average Volume 10 Days
180.7
EPS TTM
--
Shares Outstanding
30.7M
EX-Date
12/19/13
P/E TM
--
Dividend
€0.23
Dividend Yield
0.36%
Current Stock Chart for BALCHEM CORP (BL9B)

Related News

No related news articles were found.

balchem corp (BL9B) Related Businessweek News

No Related Businessweek News Found

balchem corp (BL9B) Details

Balchem Corp. develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, and medical sterilization industries, primarily in the U.S. Its encapsulated/nutritional products segment provides solutions to various applications in food, pharmaceutical, and nutritional ingredients. It also offers human-grade choline nutrient products for wellness applications and calcium carbonate products, as well as products for the animal health industry. Its specialty products segment is a leader in packaging and distributing hazardous chemicals and is the leading supplier of packaged 100% ethylene oxide to the health-care industry, where it is used as a sterilant for medical items. The Ingredients segment manufactures and supplies choline chloride, a nutrient for animal health, to the poultry and swine industries. It also manufactures derivatives of choline chloride. Balchem was founded in 1967 and is headquartered in New Hampton, N.Y.

387 Employees
Last Reported Date: 02/27/14
Founded in 1967

balchem corp (BL9B) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $653.4K
Vice President of Administration, Treasurer a...
Total Annual Compensation: $255.5K
General Counsel and Secretary
Total Annual Compensation: $204.0K
Vice President and General Manager of Special...
Total Annual Compensation: $248.0K
Compensation as of Fiscal Year 2013.

balchem corp (BL9B) Key Developments

Balchem Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Balchem Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the third quarter, the company reported net sales of $160,490,000 against $87,593,000 a year ago. Earnings from operations were $25,284,000 against $16,976,000 a year ago. Earnings before income tax expense were $23,209,000 against $17,060,000 a year ago. Net earnings were $15,178,000 million against $11,657,000 a year ago. Diluted net earnings per common share $0.49 against $0.38 a year ago. Non-GAAP earnings from operations were $32,744,000 against $17,954,000 a year ago. Non-GAAP net earnings were $20,250,000 or $0.65 per diluted share against $12,325,000 or $0.40 per diluted share a year ago. EBITDA was $35,419,000 against $19,583,000 a year ago. Adjusted EBITDA was $37,015,000 against $20,490,000 a year ago. For the nine months, the company reported net sales of $378,715,000 against $255,540,000 a year ago. Earnings from operations were $55,148,000 against $49,457,000 a year ago. Earnings before income tax expense were $51,872,000 against $49,605,000 a year ago. Net earnings were $33,804,000 against $34,127,000 a year ago. Diluted net earnings per common share were $1.09 against $1.11 a year ago. Net cash provided by operating activities was $49,241,000 against $39,872,000 a year ago. Capital expenditures and intangible assets acquired was $6,025,000 against $6,822,000 a year ago. Non-GAAP earnings from operations were $75,732,000 against $52,423,000 a year ago. Non-GAAP net earnings were $47,514,000 or $1.53 per diluted share against $36,168,000 or $1.18 per diluted share a year ago. EBITDA was $75,044,000 against $57,295,000 a year ago. Adjusted EBITDA was $86,252,000 against $60,182,000 a year ago.

Balchem Mulls Acquisitions

Balchem Corp. (NasdaqGS:BCPC) is seeking acquisitions. Dino Rossi, Balchem Corporation - Chairman, President & Chief Executive Officer said, "We will continue to explore alliances, acquisitions, and/or joint ventures to build and leverage on our strategic direction, technology, and strong human asset base, which has now more than doubled with the SensoryEffects acquisition.”

Balchem Corp. to Report Q3, 2014 Results on Nov 10, 2014

Balchem Corp. announced that they will report Q3, 2014 results at 9:30 AM, US Eastern Standard Time on Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BL9B:GR €52.95 EUR -0.24

BL9B Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aceto Corp $21.38 USD -0.19
CVR Partners LP $8.97 USD -0.06
FutureFuel Corp $12.85 USD +0.24
Innophos Holdings Inc $56.26 USD +0.98
Terra Nitrogen Co LP $95.15 USD +1.67
View Industry Companies
 

Industry Analysis

BL9B

Industry Average

Valuation BL9B Industry Range
Price/Earnings 46.5x
Price/Sales 4.4x
Price/Book 5.4x
Price/Cash Flow 45.9x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BALCHEM CORP, please visit www.balchem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.